Orphazyme's Arimoclomol Disappoints For Muscle-Wasting Disorder
Pivotal Trial Failure For ‘Pipeline-In-A-Product’
Executive Summary
The Danish biotech's stock sank after arimoclomol failed in a Phase II/III trial for inclusion body myositis. Orphazyme is hoping for much better news in the coming weeks as the US FDA makes its decision on the drug as a treatment for Niemann-Pick disease Type C.
You may also be interested in...
Sanofi Scores Clinical Win In Sixth Disease For Dupixent
The French major and partner Regeneron expect to file Dupixent for the rare skin disease next year after a Phase III trial of the blockbuster hit its primary and secondary endpoints.
Menarini And Radius Skip Into SERD Lead With Elacestrant Success
Elacestrant has become the first oral SERD to generate positive topline results in a pivotal study as a monotherapy versus standard of care for ER+/HER2- advanced or metastatic breast cancer.
Finance Watch: 2021 Biopharma VC Funding Tops Full-Year 2020 Total
Private Company Edition: The industry raised $28bn in venture capital through the third quarter, breaking the record $27.4bn raised last year. Also, big pharmas backed a start-up lab in Israel, plus mega-rounds for CinCor Pharma ($143m) and Rectify Pharmaceuticals ($100m), while Cerecin raises $40m.